Insulet estimated that its total addressable market for automated insulin delivery will grow to a $9bn market value by 2028.

Insulet’s fair value estimate has been held steady at US$377.72 per share, with only fractional tweaks to the underlying ...

Insulet (Nasdaq:PODD) announced today that it debuted at the Consumer Electronics Show (CES) 2026 in Las Vegas.

Insulet Corporation (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its debut at Consumer Electronics Show (CES) ...

PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.

Pease announced, "For the fourth quarter, we expect total Omnipod revenue growth of 27% to 30% and total company growth of 25% to 28%." She guided for fourth quarter U.S. Omnipod growth of 24% to 27% ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, and Pantone ®, the global authority on color ...

Insulet Corporation (NASDAQ:PODD) reported second-quarter adjusted earnings of $1.17 per share, beating the consensus of 92 cents. PODD shares are rallying today. Track live prices here. The automated ...

Insulet’s Q4 revenue hit $597.5 million, up 17.2%, beating the $582.81 million consensus. Omnipod revenue climbed 16.9% to $585.7 million, with international sales up 33.5%. See the seasonal trading ...

The tubeless Omnipod 5 automated insulin delivery system, launched in the United Kingdom in 2023, was associated with improved time in range (TIR) at 1 year, with no increase in time below range and ...

Aug. 26 (UPI) --The Food and Drug Administration on Monday approved Insulet's Omnipod 5 automated insulin delivery system for people with Type 2 diabetes. In 2022, the FDA signed off on the system for ...

Insulet said its Omnipod 5 automated insulin delivery system has been cleared by the Food and Drug Administration for people with type 2 diabetes. The Acton, Mass.-based company said Monday the ...